Inhaled antibiotics during mechanical ventilation-why it will work
2021 Annals of Translational Medicine. All rights reserved..
Inhaled antibiotics are a common therapy among patients suffering recurrent or chronic pulmonary infections. Their use is less frequent in acutely ill patients despite a strong theoretical rationale and growing evidence of their efficiency, safety and beneficial effect on reducing bacterial resistance emergence. Clinical trials of inhaled antibiotics have shown contradictory results among mechanically ventilated patients. The optimal nebulization setup, not always implemented in all trials, the difficulty to identify the population most likely to benefit and the testing of various therapeutic strategies such as adjunctive versus alternative to systemic antibiotics may explain the disparity in trial results. The present review first presents the reasons why inhaled antibiotics have to be developed and the benefits to be expected of inhaled anti-infectious therapy among mechanically ventilated patients. A second part develops the constraints of aerosolized therapies that one has to be aware of and the simple actions required during nebulization to ensure optimal delivery to the distal lung parenchyma. Positive and negative studies concerning inhaled antibiotics are compared to understand the discrepancies of their findings and conclusions. The last part presents current developments and perspective which will likely turn it into a fully successful therapeutic modality, and makes the link between inhaled antibiotics and inhaled anti-infectious therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Annals of translational medicine - 9(2021), 7 vom: 11. Apr., Seite 598 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Desgrouas, Maxime [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-bacterial agents |
|---|
| Anmerkungen: |
Date Revised 16.05.2021 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/atm-20-3686 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325386641 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325386641 | ||
| 003 | DE-627 | ||
| 005 | 20231225192328.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/atm-20-3686 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1084.xml |
| 035 | |a (DE-627)NLM325386641 | ||
| 035 | |a (NLM)33987296 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Desgrouas, Maxime |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inhaled antibiotics during mechanical ventilation-why it will work |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.05.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2021 Annals of Translational Medicine. All rights reserved. | ||
| 520 | |a Inhaled antibiotics are a common therapy among patients suffering recurrent or chronic pulmonary infections. Their use is less frequent in acutely ill patients despite a strong theoretical rationale and growing evidence of their efficiency, safety and beneficial effect on reducing bacterial resistance emergence. Clinical trials of inhaled antibiotics have shown contradictory results among mechanically ventilated patients. The optimal nebulization setup, not always implemented in all trials, the difficulty to identify the population most likely to benefit and the testing of various therapeutic strategies such as adjunctive versus alternative to systemic antibiotics may explain the disparity in trial results. The present review first presents the reasons why inhaled antibiotics have to be developed and the benefits to be expected of inhaled anti-infectious therapy among mechanically ventilated patients. A second part develops the constraints of aerosolized therapies that one has to be aware of and the simple actions required during nebulization to ensure optimal delivery to the distal lung parenchyma. Positive and negative studies concerning inhaled antibiotics are compared to understand the discrepancies of their findings and conclusions. The last part presents current developments and perspective which will likely turn it into a fully successful therapeutic modality, and makes the link between inhaled antibiotics and inhaled anti-infectious therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anti-bacterial agents | |
| 650 | 4 | |a critical care | |
| 650 | 4 | |a inhalation | |
| 650 | 4 | |a intensive care units | |
| 650 | 4 | |a respiration, artificial | |
| 650 | 4 | |a ventilator associated pneumonia (VAP) | |
| 700 | 1 | |a Ehrmann, Stephan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of translational medicine |d 2013 |g 9(2021), 7 vom: 11. Apr., Seite 598 |w (DE-627)NLM23455374X |x 2305-5839 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:7 |g day:11 |g month:04 |g pages:598 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/atm-20-3686 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 7 |b 11 |c 04 |h 598 | ||